Telix Pharmaceuticals (ASX:TLX) said that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorization for its prostate cancer imaging agent, Illuccix, according to a Thursday filing with the Australian bourse.
The approval allows for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer through positron emission tomography imaging, the filing said.
Illuccix will be distributed in the UK through Telix's partner, Xiel, a distributor of nuclear medicine, radiotherapy, and diagnostic radiology technologies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。